Pioneering technique paves way for fast and cheap fabrication of rapid medical diagnostic tools
Breakthrough promises to democratise microfluidics and lab-on-a-chip technology, benefiting resource-poor countries and settings.
New technology developed by the University of Bristol has the potential to accelerate uptake and development of on-chip diagnostic techniques in parts...
Nemera receives Drug Manufacturing Authorization for its Neuenburg plant, in Germany
Important achievement for Nemera, now able to handle, assemble, sterilize and store pharmaceutical drugs and medicinal products for autoinjectors.
On 4th September, Nemera received from the German Government Drug Administration (Government Presidium, Tübingen) the...
How a Novel Drug Discovery Technology Could Help in the Fight Against COVID-19
By Dr Asif Tulah, Alcyomics
Alcyomics has been adapting its service provision and assays to play their part in the race to find new treatments for COVID-19 (SARS-CoV-2) and to better understand how this virus works....
Fishing for answers to the covid conundrum
The eyes of the scientific world have been on a Covid-stricken fishing vessel that seems to have provided the first real evidence outside of a lab that antibodies do indeed protect against reinfection. By...
‘Snobbery’ is depriving people of a great career
Education Secretary hails an apprenticeship programme that is coming of age with top firms having woken up to the benefits apprentices are bringing to their workplaces
With new, higher quality apprenticeships helping people...
Nemera takes dermal treatments to millions of patients
Nemera is a world leader in design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generic industries, including complex dermal drug delivery devices.
Dermal pharmaceuticals, cosmetics and personal hygiene products all...
TWO NEW FORMS OF THERAPY GIVE HOPE WHEN BLOOD CANCER RETURNS AND BOWEL CANCER...
Scientists trial new way to boost CAR T-cell therapy
Cancer Research UK is collaborating with Aleta Biotherapeutics to trial a new therapy that reboots a treatment for some people whose blood cancer starts to come back.
The new...
Heart Disease: A primary cause of death
Dr Catrin Rutland BSc PGCHE MSc MMedSci PhD SFHEA FAS
Heart disease is one of the primary causes of death throughout the world in both humans and animals. Research at The School of Veterinary Medicine...
Controlling Temperature with BioPharma Dynamics
BioPharma Dynamics discuss the importance of controlling parameters in your process.
Temperature monitoring and control devices are an integral part of any laboratory within the pharmaceutical sector. Having a quality temperature control system in place...
Bringing patients and providers together one tweet at a time
As an open forum for human interaction, social media have become the great equalizer of health information – providing a means for patients and health care providers to connect outside of the hospital or...
Better understanding of immunology offers hope for the future
Recent years have seen dramatic strides being taken in the science of immunology – the capacity to direct the body’s natural defences against specific illnesses and conditions.
So dramatic have the strides been that scientists’...
UCL supports worldwide dissemination of free-to-access manufacturing instructions for COVID-19 breathing aids
Governments across the world, healthcare providers and device manufacturers can now request a free of charge licence to the design and manufacturing files of a breathing aid developed by UCL, UCLH and Mercedes-AMG High...
UK Institute to harness disruptive technology to transform drug discovery
Business Secretary Greg Clark has announced funding for a series of ambitious technology projects that will transform the way medicines are discovered, enabling the pharmaceutical industry to develop groundbreaking drugs faster, cheaper and better...
Oxford biotech firm secures £13.2m to develop world’s first treatment for rare, incurable and...
SynaptixBio, whose aim is to treat the genetic central nervous system disease TUBB4A-related leukodystrophy, has successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the last...
Setting up a Bio Science business – Intellectual Property
This is the first in a series of short articles on aspects of starting a bio science business
Although some very successful service businesses have been built without specific intellectual property and instead have relied...
Research deepens understanding of malaria parasite
Science carried out in Nottingham helped to form the foundation for the latest breakthrough in the global fight against malaria.
Researchers in the University of Nottingham’s School of Life Sciences were responsible for the identification...